Ovid Therapeutics (OVID) Price & Analysis

Compare

1,666 Followers

OVID Stock Chart & Stats

$1.47

-$0.03(-2.93%)

At close: Jan 08 4:00 PM EST

$1.47

-$0.03(-2.93%)

Day’s Range― - ―

52-Week Range$0.24 - $2.01

Previous CloseN/A

Volume22.63K

Average Volume (3M)1.52M

Market Cap

$104.68M

Enterprise Value$80.61M

Total Cash (Recent Filing)$25.60M

Total Debt (Recent Filing)$13.76M

Price to Earnings (P/E)―

Beta2.35

Next Earnings

Mar 16, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding71,212,360

10 Day Avg. Volume1,191,591

30 Day Avg. Volume1,521,247

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.97

Price to Sales (P/S)116.97

P/FCF Ratio-1.18

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue12.19

Enterprise Value/Gross Profit12.23

Enterprise Value/Ebitda-2.00

Forecast

1Y Price Target

$4.43

Price Target Upside201.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug Safety And EfficacyOV329, a next-generation GABA-aminotransferase inhibitor, yielded positive top-line results from a Phase 1 trial in healthy volunteers, with no treatment-related serious adverse events observed.

Leadership And Strategic DirectionCEO transition seems reasonable given the new CEO's longstanding involvement in developing novel seizure drugs, suggesting strong leadership moving forward.

Market OpportunityThe epilepsy market is favorable as the FDA wants to approve new drugs, payer pushback is relatively low, and physicians are open to trying new therapies.

Bears Say

Historical PerformanceDespite its inception in 2014, Ovid has not advanced to the ranks of commercial status due to four late-stage program failures.

Lead Molecule ConcernsThe muted stock reaction reflects plans to switch to a different lead molecule, indicating that random small-molecule-off-target risk is still to be addressed.

Safety RisksKey risks to the investment thesis include unexpected new safety signals, especially retinal toxicity for OV329.

Ovid Therapeutics News

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

Ovid Therapeutics (OVID) announced results from its Phase 1 study of OV350, the first-ever Potassium-Chloride Cotransporter 2, KCC2,...

2d ago

OVID

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

17:27 EST Ovid Therapeutics (OVID) files to sell 125.06M shares of common stock for holders Published first on...

5d ago

OVID

Ovid Therapeutics initiated with a Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $3 price...

9d ago

OVID

Ovid Therapeutics appoints Kaufmann as Chief Medical Officer

Ovid Therapeutics (OVID) announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann...

18d ago

OVID

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $2 from $1.50 and keeps a...

26d ago

OVID

Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating

Analyst Thomas Shrader of BTIG maintained a Buy rating on Ovid Therapeutics, retaining the price target of $4.00....

1d ago

OVID

Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward

William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating on...

2d ago

OVID

Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data

The latest announcement is out from Ovid Therapeutics ( ($OVID) ). On December 18, 2025, Ovid Therapeutics reported...

2d ago

OVID

Ovid Therapeutics Stockholders Approve Key Proposals

Ovid Therapeutics ( ($OVID) ) has issued an announcement. On December 11, 2025, Ovid Therapeutics held a special...

9d ago

OVID

Leerink bullish on Ovid Therapeutics, initiates with an Outperform

As previously reported, Leerink analyst Marc Goodman initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and...

1M ago

OVID

Ovid Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target Published first on...

1M ago

OVID

Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today....

1M ago

OVID

Ovid Therapeutics Reports Q3 2025 Financial Results

Ovid Therapeutics ( ($OVID) ) has released its Q3 earnings. Here is a breakdown of the information Ovid...

1M ago

OVID

Ovid Therapeutics reports Q3 EPS (17c), consensus (15c)

Reports Q3 revenue $132k, consensus $170.38k. “Ovid is operating from a position of scientific and fiscal strength. The...

1M ago

OVID

OVID FAQ

What was Ovid Therapeutics Inc’s price range in the past 12 months?

Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.

What is Ovid Therapeutics Inc’s market cap?

Ovid Therapeutics Inc’s market cap is $104.68M.

When is Ovid Therapeutics Inc’s upcoming earnings report date?

Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 86 days.

How were Ovid Therapeutics Inc’s earnings last quarter?

Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.

Is Ovid Therapeutics Inc overvalued?

According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ovid Therapeutics Inc pay dividends?

Ovid Therapeutics Inc does not currently pay dividends.

What is Ovid Therapeutics Inc’s EPS estimate?

Ovid Therapeutics Inc’s EPS estimate is -0.12.

How many shares outstanding does Ovid Therapeutics Inc have?

Ovid Therapeutics Inc has 71,212,360 shares outstanding.

What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?

Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Ovid Therapeutics Inc?

Currently, no hedge funds are holding shares in OVID

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ovid Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-60.06%

Trailing 12-Months

Asset Growth

-37.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders. The company operates primarily in the biotechnology sector and is committed to advancing treatments for conditions such as Angelman syndrome and other central nervous system disorders. Ovid's core products include its investigational drug candidates, which are designed to address the underlying causes of these disorders and improve the quality of life for affected individuals.

Ovid Therapeutics (OVID) Earnings & Revenues

Historic Earnings Reports

OVID Stock 12 Month Forecast

Average Price Target

$4.43

▲(201.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.2,2.6,3,3.4000000000000004,3.8,4.2,4.6000000000000005,5,5.4,5.8,6.2,6.6000000000000005,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.002307692307692,2.2046153846153844,2.4069230769230767,2.609230769230769,2.8115384615384613,3.0138461538461536,3.216153846153846,3.418461538461538,3.6207692307692305,3.823076923076923,4.025384615384615,4.227692307692307,{"y":4.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,1.8153846153846154,1.8307692307692307,1.8461538461538463,1.8615384615384616,1.876923076923077,1.8923076923076922,1.9076923076923078,1.9230769230769231,1.9384615384615385,1.9538461538461538,1.9692307692307693,1.9846153846153847,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >